How Semaglutide Works as oral Weight Loss drugs and in Type 2 Diabetes
For years, injectable medicines dominated the conversation around modern weight-loss treatment.
That picture is changing rapidly in 2026.
New oral weight loss drugs are now available, while researchers are also testing completely different approaches that target metabolism and skeletal muscle.
One of the most interesting experimental treatments is ATR-258, an oral beta-2 agonist being developed to improve muscle metabolism.
At the same time, oral GLP-1 medicines such as Wegovy tablets and Foundayo have moved much closer to mainstream obesity treatment.
The Rise of Oral Weight loss drugs
GLP-1 medicines work partly by reducing appetite and increasing feelings of fullness.
Semaglutide is the active ingredient in Ozempic and Wegovy.
In 2026, oral versions have become an increasingly important part of the obesity-treatment market.
Eli Lilly’s Foundayo (orforglipron) received FDA approval in April 2026 for weight management. The company reported that people taking the highest dose in the ATTAIN-1 trial lost an average of about 27 pounds.
Foundayo is taken once daily and does not have the food and water restrictions associated with some other oral GLP-1 formulations.
The UK has also authorized Foundayo, making it the first European country to approve the medicine.
Novo Nordisk’s oral Wegovy has also expanded access to semaglutide in tablet form.
The arrival of these medicines means patients who do not want injections have more options.
Why Are Oral Medicines Important?
Some people simply prefer tablets.
An oral treatment can be easier to fit into daily routines for people who dislike injections.
But convenience is only one factor.
Doctors also need to consider:
- Effectiveness
- Side effects
- Existing medical conditions
- Other medicines
- Cost
- Treatment goals
- Long-term adherence
The strongest treatment is not necessarily the best treatment for every individual.
A Different Approach: Targeting Muscle
The original research behind this article focused on an experimental treatment called ATR-258.
Unlike GLP-1 medicines, ATR-258 is designed to target skeletal muscle.
The aim is to improve muscle metabolism and glucose uptake while supporting fat utilization.
The original study reported promising findings in experimental models, including improved glucose handling and preservation of muscle mass.
This approach is different from the appetite-suppressing mechanism used by GLP-1 drugs.
Why Is Muscle Important During Weight Loss?
Weight loss is not only about reducing the number on the scale.
Muscle plays an important role in:
- Physical strength
- Movement
- Glucose metabolism
- Energy expenditure
- Long-term physical function
Significant weight loss can involve loss of lean tissue as well as fat.
That has encouraged researchers to look for treatments that could improve body composition rather than simply reducing total body weight.
What Is ATR-258?
ATR-258 is an investigational beta-2 adrenergic receptor agonist.
Researchers designed the molecule to stimulate skeletal muscle while trying to avoid excessive cardiovascular stimulation associated with older beta-2 agonists.
Early research suggested that the drug could improve glucose uptake and muscle metabolism.
The original article reported early human testing involving healthy volunteers and people with type 2 diabetes.
More recent development has continued to investigate ATR-258 in human studies.
But it is important to be clear:
ATR-258 is not an approved weight-loss medicine.
It remains an investigational treatment.
Could ATR-258 Replace Ozempic?
There is no evidence to say that yet.
GLP-1 medicines and ATR-258 work through very different mechanisms.
GLP-1 medicines primarily influence appetite, digestion and metabolic signaling.
ATR-258 is designed to act on skeletal muscle.
The research question is therefore not simply whether one drug is better than another.
Scientists are asking whether different mechanisms could eventually complement each other.
The original research also suggested the possibility of combining the muscle-targeted approach with existing GLP-1 medicines.
That remains an area for clinical investigation.
How Does This Fit Into the Larger Weight-Loss Drug Pipeline?
The obesity-treatment pipeline is becoming much more diverse.
There are now:
- Injectable GLP-1 medicines
- Oral GLP-1 medicines
- Dual and multi-receptor drugs
- Experimental muscle-targeted medicines
- Combination approaches
- Treatments designed to improve long-term weight maintenance
For a broader look at these developments, see our new weight-loss drugs and obesity treatments in 2026 in the SlimFitAffiliate Pillar Article No. 18.
Genetics May Also Explain Why Treatments Work Differently
Even with the growing number of medicines, one question remains:
Why does one person respond strongly while another responds less?
Genetics may be one part of the answer.
Our article on genetics and GLP-1 response explains new research showing that genetic differences may influence the effectiveness of GLP-1 medicines and the risk of some side effects.
That research could eventually contribute to more personalized obesity treatment.
GLP-1 Medicines May Have Effects Beyond Weight Loss
Another emerging area is the potential effect of GLP-1 medicines on alcohol use.
Research in 2026 found that oral semaglutide reduced several alcohol-related outcomes in people with moderate to severe Alcohol Use Disorder.
Our article on GLP-1 research beyond weight loss and appetite examines that development in greater detail.
This illustrates how quickly scientists are discovering new possible roles for metabolic medicines.
What Are the Main Questions About ATR-258?
Researchers still need to determine:
- Whether the metabolic benefits seen in early studies translate into meaningful human weight loss
- Whether muscle mass is preserved during significant weight reduction
- Whether the treatment is safe over longer periods
- Whether it can improve type 2 diabetes
- Whether it can work alongside GLP-1 medicines
- Which patients could benefit most
These questions cannot be answered by early laboratory or small human studies alone.
Why the Future May Be About Better Weight Loss, Not Just More Weight Loss
The next generation of obesity medicines may focus on more than the number on the scale.
Researchers increasingly want to achieve:
fat loss + muscle preservation + improved blood sugar + better metabolic health + long-term maintenance.
That could lead to more personalized treatment strategies.
Oral GLP-1 medicines are already becoming a real treatment option.
Muscle-targeted drugs such as ATR-258 remain experimental.
Keeping those two categories separate is important.
Final Thoughts
The obesity-treatment field is moving quickly.
Oral medicines such as Foundayo and oral Wegovy are making treatment more convenient for people who prefer tablets.
At the same time, experimental medicines such as ATR-258 are testing a very different idea: targeting skeletal muscle and metabolism rather than primarily suppressing appetite.
The future could eventually combine several approaches.
But ATR-258 still needs more clinical testing before it can be considered an established obesity treatment.
Medical Disclaimer
This article is for educational purposes only and is not medical advice. ATR-258 is an investigational medicine and should not be used outside an appropriately authorized clinical research setting. Always consult a qualified healthcare professional before starting, stopping or changing prescription medication.
References
- FDA/Lilly — Foundayo (orforglipron) approval
- JAMA — FDA Approval of Orforglipron
- ClinicalTrials.gov — ATR-258 research
- Cell — Research into muscle-targeted beta-2 agonist treatment
#WeightLossDrugs #GLP1 #OralGLP1 #ObesityTreatment #WeightLossResearchOral weight losss
Written by Ravi Tiku
Publisher & Author | 38 Years of Pharmaceutical Sales Experience
[Medical information note: This article is for general educational purposes and is not a substitute for professional medical advice.]